PT2874630T - Regime de dosagem para inibidores de janus quinase (jak) - Google Patents

Regime de dosagem para inibidores de janus quinase (jak)

Info

Publication number
PT2874630T
PT2874630T PT13742573T PT13742573T PT2874630T PT 2874630 T PT2874630 T PT 2874630T PT 13742573 T PT13742573 T PT 13742573T PT 13742573 T PT13742573 T PT 13742573T PT 2874630 T PT2874630 T PT 2874630T
Authority
PT
Portugal
Prior art keywords
jak
kinase inhibitors
janus kinase
dose scheme
inhibitors dose
Prior art date
Application number
PT13742573T
Other languages
English (en)
Portuguese (pt)
Inventor
J Gonzales Andrea
B Cosgrove Sallie
B Malpas Phyllis
Rolf Stegemann Michael
Turner Collard Wendy
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2874630(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PT2874630T publication Critical patent/PT2874630T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT13742573T 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak) PT2874630T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25

Publications (1)

Publication Number Publication Date
PT2874630T true PT2874630T (pt) 2019-01-31

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13742573T PT2874630T (pt) 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak)

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN108354938A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2958921T1 (sl) 2013-02-22 2017-12-29 Pfizer Inc. Derivati pirolo(2,3-d)pirimidina kot inhibitorji Janus kinaz (JAK)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
FI3915989T3 (fi) * 2019-01-30 2023-09-20 Felicamed Biotechnology Co Ltd Jak:n estäjä ja sen valmistusmenetelmä
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
US11827657B2 (en) 2020-12-18 2023-11-28 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
US20240300943A1 (en) * 2021-03-16 2024-09-12 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
WO2022222948A1 (zh) * 2021-04-22 2022-10-27 深圳微芯生物科技股份有限公司 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916833T2 (de) * 1998-06-19 2005-04-14 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-verbindungen
ES2467109T3 (es) 2008-08-20 2014-06-11 Zoetis Llc Compuestos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
JP2017019816A (ja) 2017-01-26
CN108354938A (zh) 2018-08-03
LT2874630T (lt) 2019-02-11
JP2015522620A (ja) 2015-08-06
DK2874630T3 (en) 2019-01-28
ES2707627T3 (es) 2019-04-04
CN104470525A (zh) 2015-03-25
KR20150028299A (ko) 2015-03-13
AU2013292547B2 (en) 2017-05-04
CA2878867C (en) 2018-01-09
HRP20182088T1 (hr) 2019-02-08
CY1121436T1 (el) 2020-05-29
HK1252083A1 (zh) 2019-05-17
IN2015DN00370A (enExample) 2015-06-12
SMT201900044T1 (it) 2019-02-28
MX2015000871A (es) 2015-05-07
EP2874630A1 (en) 2015-05-27
JP6022063B2 (ja) 2016-11-09
RS58242B1 (sr) 2019-03-29
WO2014015107A1 (en) 2014-01-23
ZA201500134B (en) 2016-08-31
AU2013292547A1 (en) 2015-01-22
KR20170034949A (ko) 2017-03-29
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
HUE042771T2 (hu) 2019-07-29
BR112015000808A2 (pt) 2017-06-27
CA2878867A1 (en) 2014-01-23
US20150126535A1 (en) 2015-05-07
NZ703152A (en) 2016-03-31
PL2874630T3 (pl) 2019-04-30
SI2874630T1 (sl) 2019-04-30
US9522151B2 (en) 2016-12-20
EP2874630B1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
PT2874630T (pt) Regime de dosagem para inibidores de janus quinase (jak)
IL265007B (en) Pyrazolopyrimidine compounds as kinase inhibitors
DK2710007T3 (da) Kinasehæmmere
DK2903618T3 (da) Rho-kinase-inhibitorer
ZA201406688B (en) Serine, threonine kinase inhibitors
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
CO6970602A2 (es) Inhibidores de quinasa
IL242453B (en) Bipyrazole derivatives as jak inhibitors
BR112015002709A2 (pt) novos compostos de pirrolopirimidina como inibidores de proteínas quinases
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
EP2900668A4 (en) INHIBITORS OF MULTIPLE KINASE PATHWAYS
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
DK2917210T3 (da) Alk kinase-inhibitorer
PL2634185T3 (pl) Inhibitory kinazy TYK2
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
IL228567A0 (en) Imidazopyridazines as akt kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
CO6990735A2 (es) Inhibidores de pirazina cinasa
EP2968358A4 (en) NOVEL CHOLINKINASE INHIBITORS
HUE036347T2 (hu) Aminokinazolin-kináz-inhibitor prodrogjai
BR112014033056A2 (pt) inibidores da proteína quinase
BR112014029718A2 (pt) inibidores da proteína quinase
AP2015008532A0 (en) Syk kinase inhibitors as treatment for malaria